Document Detail

Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
MedLine Citation:
PMID:  7539668     Owner:  NLM     Status:  MEDLINE    
In 54 patients with malignant lymphoma, haematopoietic recovery after high-dose chemotherapy and autologous bone marrow transplantation (BMT) was compared between patients randomised to receive 10 or 30 micrograms/kg/day of r-metHuG-CSF (filgrastim) or no growth factor. After standard high-dose chemotherapy with cyclophosphamide, etoposide and BCNU (CVB regimen for patients with Hodgkin's disease) or BCNU, etoposide, cytosine arabinoside and melphalan (BEAM regimen for patients suffering from non-Hodgkin's lymphoma) followed by autologous BMT, r-metHuG-CSF was administered by continuous intravenous infusion from the first day after autologous BMT until neutrophil recovery. When the r-metHuG-CSF groups were compared with the control group the major findings were: the median time to reach an absolute neutrophil count (ANC) > or = 0.5 x 10(9)/L was 20 days in the control group and 12 and 14 days, respectively, in the r-metHuG-CSF groups (P = 0.0004). The duration of neutropenia (ANC < 0.5 x 10(9)/L) was reduced from 27 days in the control group to 11 and 13 days in the r-metHuG-CSF groups (P = 0.0001). In addition, fewer days of febrile neutropenia were observed in the r-metHuG-CSF groups (5 and 6 days) than in the control group (10 days; P = 0.036). No significant effects of r-metHuG-CSF administration on the number of days with fever, the use of intravenous antibiotics and hospitalisation were detected. R-metHuG-CSF was well tolerated without any serious side-effects.(ABSTRACT TRUNCATED AT 250 WORDS)
N Schmitz; P Dreger; A R Zander; G Ehninger; H Wandt; A A Fauser; H J Kolb; A Zumsprekel; A Martin; T Hecht
Related Documents :
2040038 - Antiemetic activity of high-dose methylprednisolone associated with continuous-infusion...
12634728 - Successful mobilization of peripheral blood stem cells after addition of ancestim (stem...
3071348 - Phase i study of recombinant dna granulocyte macrophage colony stimulating factor.
1829668 - Ondansetron--the first of a new class of antiemetic agents.
578688 - The biologic response to titanium phosphate. a new synthetic mineral fiber.
1670598 - Pretreatment with d-tubocurarine, vecuronium, and pancuronium attenuates succinylcholin...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Bone marrow transplantation     Volume:  15     ISSN:  0268-3369     ISO Abbreviation:  Bone Marrow Transplant.     Publication Date:  1995 Feb 
Date Detail:
Created Date:  1995-07-07     Completed Date:  1995-07-07     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8702459     Medline TA:  Bone Marrow Transplant     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  261-6     Citation Subset:  IM    
Department of Internal Medicine II, University of Kiel, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Marrow Transplantation*
Fever / chemically induced
Graft Rejection / prevention & control*
Granulocyte Colony-Stimulating Factor / administration & dosage*,  adverse effects
Hodgkin Disease / mortality,  surgery*
Lymphoma, Non-Hodgkin / mortality,  surgery*
Middle Aged
Neutropenia / chemically induced
Recombinant Proteins / administration & dosage,  adverse effects
Survival Analysis
Transplantation, Autologous
Reg. No./Substance:
0/Recombinant Proteins; 121181-53-1/Filgrastim; 143011-72-7/Granulocyte Colony-Stimulating Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prophylaxis for acute graft-versus-host disease following unrelated donor bone marrow transplantatio...
Next Document:  Generation of rubella virus-neutralising antibodies by vaccination with synthetic peptides.